Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARGD-RR
- Development stage
- Preclinical
- Lead developer
- National Cheng Kung University
- Modality
- Peptides
01
Overview
ARGD-RR (also known as ARGDRR) is a novel recombinant dual-effect disintegrin peptide derived from snake venom (specifically, a mutant of rhodostomin where the RGD loop sequence 50PRGDMP55 is replaced with 50ARGDRR55). It exhibits high binding affinity for integrins αIIbβ3 and αvβ3. By targeting these integrins, ARGD-RR inhibits platelet activation and neutrophil extracellular trap (NET) formation, thereby preventing platelet-neutrophil interactions and subsequent inflammation. ARGD-RR is being developed for the prevention and treatment of acute kidney injury (AKI) and its transition to chronic kidney disease (CKD), as well as renal fibrosis, without causing the bleeding or thrombocytopenia side effects typically associated with conventional αIIbβ3 antagonists.
- Other names
- disintegrin-ARGDRRrhodostomin-RGDRR mutantRn-RR
02
Targets
GPIIb/IIIa (Integrin alpha-IIb/beta-3)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on ARGD-RR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARGD-RR.